Sean P. Nolan is a businessperson who has been at the head of 6 different companies. Mr. Nolan occupies the position of Executive Chairman for Istari Oncology, Inc., Chairman of Encoded Therapeutics, Inc., Chairman of Taysha Gene Therapies, Inc. and Chairman & President at Nolan Capital LLC.
He is also on the board of Ventas, Inc., Affinia Therapeutics, Inc. and Social Capital Suvretta Holdings Corp. II.
He previously was Chief Commercial Officer for Reata Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Novartis Gene Therapies, Inc., President & Chief Commercial Officer at Lundbeck, Inc., Chief Business Officer & Executive Vice President at InterMune, Inc. and Vice President-Marketing & Sales Operations at OVATION Pharmaceuticals, Inc.
Mr. Nolan received an undergraduate degree from John Carroll University.
What is Sean P. Nolan's net worth?
The estimated net worth of Sean P. Nolan is at least $3.09 million as of August 16th, 2023. Mr. Nolan owns 1,535,545 shares of Taysha Gene Therapies stock worth more than $3,086,445 as of December 18th. This net worth estimate does not reflect any other assets that Mr. Nolan may own. Additionally, Mr. Nolan receives a salary of $925,330.00 as Director at Taysha Gene Therapies. Learn More about Sean P. Nolan's net worth.
How old is Sean P. Nolan?
What is Sean P. Nolan's salary?
How do I contact Sean P. Nolan?
Has Sean P. Nolan been buying or selling shares of Taysha Gene Therapies?
Sean P. Nolan has not been actively trading shares of Taysha Gene Therapies during the past quarter. Most recently, on Wednesday, August 16th, Sean P. Nolan bought 444,444 shares of Taysha Gene Therapies stock. The stock was acquired at an average cost of $0.90 per share, with a total value of $399,999.60. Following the completion of the transaction, the chief executive officer now directly owns 1,535,545 shares of the company's stock, valued at $1,381,990.50. Learn More on Sean P. Nolan's trading history.
Who are Taysha Gene Therapies' active insiders?
Are insiders buying or selling shares of Taysha Gene Therapies?
In the last twelve months, Taysha Gene Therapies insiders bought shares 1 times. They purchased a total of 1,333,333 shares worth more than $2,999,999.25. The most recent insider tranaction occured on June, 27th when Major Shareholder Paul B Manning bought 1,333,333 shares worth more than $2,999,999.25. Insiders at Taysha Gene Therapies own 2.7% of the company.
Learn More about insider trades at Taysha Gene Therapies. Information on this page was last updated on 6/27/2024.
